Loading clinical trials...

RECRUITING

Tau PET/CT in Various Tau-Related Disease Patients

NCT06690983•Tianjin Medical University

Summary

To evaluate the potential usefulness of 18F-S16/T807 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various Tau-related disease patients.

Detailed Description

Subjects with various Tau-related disease patients underwent 18F-S16/T807 PET/CT either for an initial assessment or for recurrence detection. Lesions uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 18F-S16/T807 PET/CT were calculated.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Tau PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion Criteria

•\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Locations (2)

The First Affiliated Hospital of University of Science and Technology of China

Hefei, Anhui, China

Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, China

Key Dates

Start Date

August 1, 2018

Primary Completion Date

November 1, 2027

Completion Date

December 1, 2027

Last Updated

February 11, 2025

Enrollment

500

ESTIMATED participants

Conditions

TauopathiesNeurodegenerative DiseasesNeurodegeneration

Interventions

18F-S16/T807

DIAGNOSTIC_TEST

Contacts

Ying Wang, MD

CONTACT

+8618702292537 macrossplusvoices@163.com

Shaobo Yao, PhD

CONTACT

+862260362190 yaoshaobo008@163.com

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

NCT05508789

Alzheimer DiseaseDementia+7 more

View study

RECRUITINGEARLY_PHASE1

Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A

NCT06932809

Tauopathies

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 11, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Tau PET/CT in Various Tau-Related Disease Patients

Inclusion Criteria

Exclusion Criteria

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A

Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia

Slow-SPEED-NL: Slowing Parkinson's Early Through Exercise Dosage-Netherlands

Shanghai At Risk for Alzheimer's Disease: a Cohort Study

China Longitudinal Aging and Cognitive Impairment Study